Long-term Safety and Efficacy of Difelikefalin in Subjects With Chronic Kidney Disease–Associated Pruritus: Analysis From KALM-1 and KALM-2

Main Article Content

Steve Fishbane
Warren Wen
Catherine Munera
Frédérique Menzaghi
Kieran McCafferty

Keywords

safety, efficacy, difelikefalin, CKD, pruritis

Abstract

N/A

References

1. Albert-Vartanian A, et al. J Clin Pharm Ther. 2013;9:e23-e31.

2. Aldrich JV, et al. Drug Discov Today Technol. 2016;41:371-382.

3. Spencer RH, et al. J Am Soc Nephrol. 2016;27:338A.

4. Fishbane S, et al. N Engl J Med. 2020;382:222-232.

5. Wooldridge TD, et al. J Am Soc Nephrol. 2020;31(suppl):22-23.

6. Korsuva [package insert]. Stamford, CT: Cara Therapeutics, Inc.; August 2021.

7. Elman S, et al. Br J Dermatol. 2010;162:587-593.

8. United States Renal Data System. 2020 USRDS Annual
Data Report: Epidemiology of kidney disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive and
Kidney Diseases, Bethesda, MD, 2020.